Valeant Pharmaceuticals International (VRX) stock prices updated...
 

Valeant Pharmaceuticals International stock price

Valeant Pharmaceuticals International latest news:


  • 08/22/2017 15:07:20

    BRIEF-Valeant director Richard Deschutter reports purchase of 10,000 shares of co's common stock

    Valeant Pharmaceuticals International Inc(VRX). * Valeant director Richard Deschutter reports purchase of 10,000 shares of co's common stock on Aug. 21 - SEC filing Source text for Eikon: Further company coverage:

  • 08/17/2017 10:15:02

    Valeant Pharmaceuticals Gets Boost From FDA Update


  • 08/17/2017 09:45:15

    CANADA STOCKS-TSX barely higher as bank gains offset slips in miners

    TORONTO, Aug 17 (Reuters) - Canada's main stock index edged higher on Thursday, as declines in mining stocks partly offset gains for several heavyweight banks and a jump in shares of Valeant Pharmaceuticals International Inc.

  • 08/16/2017 14:49:26

    Valeant Pharma works to resolve FDA concerns at Tampa plant

    Valeant Pharmaceuticals International Inc. shares ticked higher in the extended session Wednesday after the drugmaker said that issues from a Food and Drug Administration inspection were being resolved. Valeant shares rose 1% to $14.30 after hours. Valeant said an inspection of its Bausch & Lomb plant in Tampa, Fla., turned up some "manufacturing uncertainties" but a collaboration with FDA inspectors to resolve the issues will result in a Voluntary Action Indicated certification, where objectionable concerns were observed by inspectors but were not significant from a regulatory standpoint.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/09/2017 18:21:42

    BRIEF-Hedge fund Paulson & Co trims stake in Valeant

    Aug 10 (Reuters) - Valeant Pharmaceuticals International Inc -

  • 08/08/2017 10:39:54

    Valeant is on track to reduce about $5 billion of debt. But it has more than $27 billion to go

    The company' carries more debt than it should,' its chief financial officer says. Valeant Pharmaceuticals International Inc. (VRX) shares surged 7.9% in extremely heavy morning trade Tuesday after the company reported second-quarter earnings. Though the company reported a loss and cut its 2017 revenue guidance, the quarter's bright spots included a revenue beat and strong organic growth for Valeant's Bausch+ Lomb international segment and Salix business.

  • 08/08/2017 05:42:51

    UPDATED: Valeant stock surges 7.9% after Q2 loss, 2017 revenue guidance cut

    Valeant Pharmaceuticals International Inc. shares surged 7.9% in premarket trade on Tuesday after the company reported a second-quarter loss and cut its 2017 revenue guidance. The company reported a loss of $38 million, or a loss of 11 cents per share, compared with a loss of $302 million, or a loss of 88 cents per share in the year-earlier period. The FactSet adjusted earnings-per-share consensus was 94 cents. Revenue declined to $2.233 million from $2.42 million, above the FactSet consensus of $2.228 million. Valeant also cut its 2017 revenue guidance to $8.70 to $8.90 billion from $8.90 to $9.10 billion. Valeant shares have surged 5.9% year-to-date, compared with a 10.8% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/08/2017 05:16:56

    Valeant reports Q2 loss, cuts 2017 revenue guidance

    Valeant Pharmaceuticals International Inc. reported a second-quarter loss and cut its 2017 revenue guidance early Tuesday. The company reported a loss of $38 million, or a loss of 11 cents per share, compared with a loss of $302 million, or a loss of 88 cents per share in the year-earlier period. The FactSet adjusted earnings-per-share consensus was 94 cents. Revenue declined to $2.233 million from $2.42 million, above the FactSet consensus of $2.228 million. Valeant also cut its 2017 revenue guidance to $8.70 to $8.90 billion from $8.90 to $9.10 billion. Valeant shares have surged 5.9% year-to-date, compared with a 10.8% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/27/2017 11:02:58

    ADP stock jumps 10% in midday trade on reports of Ackman stake

    Shares of Automatic Data Processing Inc. jumped more than 10% in Thursday afternoon trade following a Bloomberg News report that Bill Ackman's Pershing Square Capital Management had taken a stake in payroll company ADP . Bloomberg cited people familiar with the matter, indicating that Ackman had recently bought shares in ADP and that he may increase his position. The report didn't specify the size of the activist investor's position. ADP's shares have climbed 13.1% so far this year, compared with a 10.1% year-to-date return for the Dow Jones Industrial Average, a 10.6% rise for the S&P 500 index thus far in 2017, and a 20% surge for the Nasdaq Composite Index over the same period. Ackman has been notably linked to recent bullish bets on Valeant Pharmaceuticals International Inc. , which he exited in March after racking up a $4 billion loss on his investment. He is also notoriously wagering that nutritional-supplement company Herbalife Ltd.'s shares will fall to zero. However, that company's stock is up 40% so far this year.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Valero Energy CorporationVLO | Valero Energy Partners LPVLP | ValhiVHI | Validus HoldingsVR | Valley National BancorpVLY | Valley National BancorpVLY.WS | Valley National BancorpVLY^A | Valmont IndustriesVMI | Valspar Corporation (The)VAL | VantivVNTV |